Serrano-Jaén L, Méndez-Tovar LJ, Almeida-Arvizu V, Manzano-Gayosso P, Córdova-Martínez E, Bazán-Mora E, Hernández-Hernández F, López-Martínez R

Language: Spanish
References: 19
Page: 415-417
PDF size: 494.04 Kb.

ABSTRACT

A 39 years old man with a long-standing disseminated dermatophytosis even with several antifungal treatments is presented. From lesions, Trichophyton rubrum var. typical downy, T. tonsurans and Candida albicans were isolated and showed sensivity to azolic compaunds in vitro. The phagocytic activity in vitro compared with normal control was depressed. Treatment with itraconazole and immunomodulation using a bacterial antigen was indicated. During the last two years the patient has been clinical and mycologically healthy, and his phagocytosis activity has become normal. In patients with chronic and relapsing dermatophytosis, the immune response evaluation is recommended, and immunomodulation could be useful as a rational measure in patients with a particular immunodeficiency.

REFERENCES

1. Akiba H, Motoki Y, Satoh M, Iwatsuki K, Kaneko F. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol. 2001;11:58-62.

2. Kalibala S. Skin conditions common to people with HIV infection or AIDS. AIDS Action 1990;10:2-3.

3. Porro MA, Yoshioka MCN, Kaminski SK, Palmeira MC, Fischman O, Alchorne MMA. Disseminated dermatophytosis caused by Microsporum gypseum in two patients with the acquired immunodeficiency syndrome. Mycopathologia 1997;137:9-12.

4. Huntley AC. The cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1982;7:427-455.

5. Radentz WH. Opportunistic fungal infections in immunocompromised hosts. J Am Acad Dermatol 1989;20:989-1003.

6. Baehner RL, Bocker LA, Davis J. Biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polimorphonuclear leukocyte. Blood 1976;48:309-313.

7. Kaminsky G. Kaminski’s Dermatophytes Scheme. http.//www.mycology. adelaide.edu.

8. Rubio-Calvo MC, Gil-Tomas J, Ruesca RB. Valoración in vitro de la sensibilidad a los antifúngicos. Rev Iberoam Micol 1996;13:S60-S63.

9. Busquet J, Lockey RF, Manning HJ (guest editors). WHO Position paper. Allergen immunotherapy: therapeutic vaccines on allergic diseases. Allegy 1998;53(suppl 1):1-42.

10. Doncker (de) P, Gupta AK, Marynissen G, Stoffels P, Hereman A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview. J Am Acad Dermatol 1997;37:969-974.

11. Burkhart CN, Chang H, Gottwald L. Tinea corporis in human immunodeficiency virus-positive patients: case report and assessment of oral therapy. Int J Dermatol 2003;42:839-843.

12. Squeo RF, Beer R, Silvers D, Weitzman I, Grossman M. Invasive Trichophyton rubrum resembling blastomycosis infection in the immunocompromised host. J Am Acad Dermatol. 1998;39:379-380.

13. Roilides E, Lyman CA, Panagopoulou P, Chanock S. Immunomodulation of invasive fungal infections. Infec Dis Clin North Am 2003;17:193:219.

14. Bjorksten B. Evidence of probiotics in prevention of allergy and asthma. Curr Drugs Targets Inflamm Allergy 2005;4:599-604.

15. Kilpimaa J, Van de Casteele T, Jokinen I, Mappes J, Alatalo RV. Genetic and enviromental variation in antibody and T-cell mediated responses in great tit. Int J Org Evolution 2005;59:2483-2489.

16. Wright RJ. Stress and atopic disorders. J Allergy Clin Immunol 2005;116:1301-1306.

17. Chapman MD. Asthma in the third world: can enviromental intervention improve childhood asthma in U. S. Inner cities? Ann Allergy Asthma Immunol 2005;95:496-497.

18. Rovere-Querini P, Manfredi AA, Sabbadini MG. Enviromental adyuvants apoptosis and the censorship over autoimmunity. Autoimmun Rev 2005;4:555-560.

19. Méndez-Tovar LJ, Serrano-Jaén L, Almeida-Arvizu VM. Cefotaxima más amikacina asociadas a inmunomodulación en el tratamiento de actinomicetoma resistente a tratamiento convencional. Gac Med Mex 1999;135:517-521.